Brain cancer module: QLQ-BN Scope. The brain cancer module is meant for use among brain cancer patients varying in disease stage and treatment. The EORTC QLQ-BN20 questionnaire for assessing the health-related quality of life (HRQoL) in brain cancer patients: A phase IV validation. To be used in conjunction with the EORTC QLQ-C30 for measuring the health- related quality of life in patients with brain cancer.

Author: Nilkis Brasho
Country: Germany
Language: English (Spanish)
Genre: Video
Published (Last): 9 July 2012
Pages: 425
PDF File Size: 9.53 Mb
ePub File Size: 20.98 Mb
ISBN: 139-4-40299-415-1
Downloads: 59725
Price: Free* [*Free Regsitration Required]
Uploader: Tojasar

EORTC Quality of Life Questionnaire – Brain Cancer Module (EORTC QLQ-BN20)

In both trials, HRQoL was measured as a secondary end point at baseline, during treatment, and on several follow-up occasions after the end of treatment.

Adjuvant procarbazine, lomustine, and vincristine improves qlq-bn2 survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: From This Paper Figures, tables, and topics from this paper. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by eortd Folstein Mini-Mental State Examination.

Changes in MMSE of 4 or more points have been considered in the literature as clinically significant [ 2223 ]. Qual Life Res ; The estimates generally agree with the estimates of 5—10 units of the QLQ-C30 scales we considered and as proposed oertc Osoba et al. Showing of 3 extracted citations.

Quality of life and physical limitations in qlq-gn20 brain tumor patients Mariana Rodrigues GazzottiSuzana M. To further clarify the issue of MCIDs, the findings from the anchor-based approach were compared with selected distribution-based techniques. By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy PolicyTerms of Serviceand Dataset License. Citations Publications citing this paper.

EORTC QLQ-BN20 – EORTC Quality of Life Questionnaire – Brain Cancer Module

The QLQ-BN20 contains 20 items, 13 of which aggregate into four scales assessing future uncertainty, visual disorder, motor dysfunction MDand communication deficit. Illness intrusiveness and subjective well-being in patients with glioblastoma Kim EdelsteinLinda E. Is a patient’s self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients?


Had we used a one-category change in the point Karnofsky performance scale, our results would probably differ. Table 5 presents distribution-based MCID estimates for comparison with anchor-based estimates in Tables 3 and 4. Further investigation, if possible with other anchors, is therefore recommended. Citing articles via Web of Science Distribution-based approaches hinge on the statistical features of the HRQoL data.

These estimates can help clinicians evaluate changes in HRQoL over time, assess the value of a health care intervention and can be useful in determining sample sizes in designing future clinical trials. Other studies [ 1213 ] have also found only moderately strong correlations of the anchors with the HRQoL scores; the reason s are unknown. A threshold of 0. Molecular targeted therapies and chemotherapy in malignant gliomas.

Anchor-based methods link HRQoL measures to external criteria, either to a known indicator that has clinical relevance [e. Thus, every eorct contributing to this question is important. For each analysis, patients with data on an anchor and HRQoL scores at 2 or more time points were included. This is in contrast to a number of studies [ 121326 ] that have found that MCID estimates for deterioration were larger than those for improvement.

Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Insufficient sleep and fitness to drive in shift workers: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: The MMSE [ 21 ] is a test with eorrtc point maximum score, which is used to screen for cognitive impairment.

Since the results for T 1 and T 2 were very similar, only the results at T 1 are reported. This article has been cited by 1 Prospective assessment of quality of life in adult patients qlq-bj20 primary brain tumors in routine neurooncology practice Budrukkar, A. Trial 2 reported by van den Bent et al. For interpretation, it could be recommended to augment the anchor-based MCID estimates with results from one of the distribution-based approaches by considering only qlqq-bn20 anchor-based MCID estimates at least equal to 0.


Prosthetics and Orthotics International. Van Den Bent, R.

The two points furthest apart in time, denoted by T 1 and T 2provided a better chance of observing changes in HRQoL scores and were therefore used for analysis. Note that patients could be categorized differently between the anchor and HRQoL measures, e. Topics Discussed in This Paper.

Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases.

In light of this, we restricted analysis of physical and role functioning domains only to the most recent version of the questionnaire; the one that uses the 4-point scale. Changes in PS were categorized into three groups: These anchors are clearly definable, understandable, and are commonly used by clinicians in assessment of cancer patients and could therefore help guide interpretation of HRQoL scores.

Sign In or Create an Account. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of cancer therapy FACT anemia and fatigue scales. Some authors suggest that 0. Selected baseline demographic and clinical characteristics of the patients.

Analysis of health-related quality of life in patients with brain tumors prior and subsequent to radiotherapy. Determining the minimal clinically important difference MCID [ 1 ] for HRQoL scores from cancer clinical trials is useful to clinicians, patients, and researchers as a benchmark for assessing the effectiveness of a health care intervention and for determining the sample size in a clinical trial.

Differences that are statistically significant are indicated by asterisk. These thresholds may also vary across patient groups.

In general, the anchor-based MCID estimates tended to be larger than the 0.